A study published in the Journal of Clinical Oncology suggested that in patients with advanced chronic lymphocytic leukemia (CLL), a high dose (5 x 108) of CAR T-19 may be more effective than a low dose (5 x 107) at inducing a complete response (CR) without excessive toxicity.
However, the researchers also indicated that attainment of a CR after CAR T-19 infusion, regardless of cell dose, is correlated with longer overall survival (OS) and progression-free survival (PFS) in patients with relapsed CLL.
“To our knowledge, the study we report here represents the largest cohort of prospectively enrolled patients with CLL to receive CAR T-cells and with the longest follow-up,” the authors wrote. “We sought to determine an association of cell dose with response or toxicity in CLL.”
Between January 2013 and June 2016, researchers enrolled 42 patients with relapsed or refractory…